What If I Have a Low BMI, Am Post-Menopausal, or a Man?Updated 3 months ago

Bondia™ is designed for the dietary management of osteopenia and bone loss associated with menopause, age, and weight. It has been evaluated in a double-blind, placebo-controlled clinical trial with 286 women between 1 and 6 years post-menopause. 

The results are currently pending peer review and publication. Bondia reduced bone loss in women with osteopenia, women with an elevated BMI, and women with an elevated body fat percentage. Women with osteoporosis were not included in this clinical study.

Bondia was evaluated in women in the years following menopause because it is well understood that women experience rapid bone loss in this period of life. Bone is a living tissue that is continually remodeled by cells in our bodies. For most men and women, bone density peaks around 30 years of age and slowly declines through the remainder of life as the activity of osteoclasts (cells that break down bone) outpaces the activity of osteoblasts (cells that build bone). 

Researchers at Journa Health have shown that Bondia reduces osteoclast activity in preclinical models, so Bondia may have protective effects on bone density in populations outside of those studied in our clinical trial of early post-menopausal women.

Clinical studies using Bondia in other populations have not been completed at this time. However, Journa is collaborating with researchers at the Marcus Institute for Aging Research to perform a clinical study on the effects of Bondia for preserving bone mass in women over age 60 (STARS: Synbiotic to Attenuate Resorption of the Skeleton).

Bondia™ is generally recognized as safe (GRAS). In our clinical trials, there was no difference in side effects between placebo and Bondia™, indicating that it is safe and well tolerated. Bondia may be a beneficial addition to your overall health management strategy. However, we recommend consulting with your healthcare provider on any changes to managing your health."